Blue Finessence
Blue Finessence
  • Home
  • About Us
  • Services
    • Our Services
    • Company Formation in Europe
  • News
    • Internal News
    • General news
  • Contact
  • Your cart is currently empty.

    Sub Total: $0.00 View cartCheckout

FDA Says Many Fitness Wearables, AI Tools Exempt From Regulation

Home / Finance / FDA Says Many Fitness Wearables, AI Tools Exempt From Regulation
FDA Says Many Fitness Wearables, AI Tools Exempt From Regulation
  • January 9, 2026
  • test
  • 24 Views

FDA Says Many Fitness Wearables, AI Tools Exempt From Regulation

FDA Says Many Fitness Wearables, AI Tools Exempt From Regulation

The Food and Drug Administration on Jan. 6 clarified that it will not regulate some artificial intelligence (AI) tools and wearables.

In a guidance document, the Food and Drug Administration (FDA) said tools used to help make clinical decisions are sometimes exempt from FDA oversight, such as those not intended to analyze medical images.

In a second document, the FDA said it does not regulate “low risk products that promote a healthy lifestyle,” including “low risk general wellness products” such as exercise equipment and software programs.

The agency listed as examples products that track and record a person’s sleep, work, and exercise and products that make claims about weight management and physical fitness.

“For a lot of the decision support out there, we need to get out of the way as a regulator,” FDA Commissioner Marty Makary said in a video. “We have a clear lane for medical-grade products. But otherwise, we need to adapt with the times, and be proactive with guidance, so that companies and developers are not left confused about what they should be doing, or what the FDA wants.”

Food and Drug Administration Commissioner Marty Makary in Washington on July 29, 2025. Saul Loeb/AFP via Getty Images

As Zachary Stieber details below via The Epoch Times, Makary said the FDA is “here to promote AI” and added during an appearance on Fox Business that at least some of the tools use AI.

“If something is simply providing information, like ChatGPT or Google, we’re not going to outrun that lion, we’re not going to go in there and say there is one result that is inaccurate and therefore we have to shut down,” Makary said. “We have to promote these products, and at the same time, just guard against major safety concerns.”

When asked about concerns regarding inaccurate information, Makary said, “We don’t believe in censorship.”

“If people are looking up a symptom on an AI-based tool, let’s have that conversation when they come in to see their doctor or do a virtual visit,” he said.

OpenAI, which developed ChatGPT, said this month that more than 5 percent of ChatGPT messages are about health care, with more than 40 million users turning to the AI bot with health care questions.

Researchers reported in 2025 that at least half of responses from AI models to health-related questions are not fully supported by their sources and that some answers are contradicted by the sources.

Wearables, a category that includes fitness trackers and glucose monitors, are also not subject to regulatory oversight if they are simply providing information, according to Makary.

“The only stipulation is if they make claims of something being medical grade, like a clinically appropriate clinical-grade blood pressure measurement,” he said on Fox. “We don’t want people changing their medicines based on something that’s just a screening tool or an estimate of a physiologic parameter.”

Health Secretary Robert F. Kennedy Jr. has said people should start using wearables as part of efforts to improve their health.

The FDA had in 2025 warned Whoop, which makes wearable products, that it was marketing monitoring of blood pressure without FDA approval.

“We believe the agency is overstepping its authority in this case by attempting to regulate a non-medical wellness feature as a medical device,” a Whoop spokesperson told news outlets at the time.

The FDA later issued consumer alerts telling people not to use unauthorized devices for monitoring blood pressure and infant vital signs.

Tyler Durden
Thu, 01/08/2026 – 13:45

Tyler DurdenSource

Share:

Previus Post
Interpello: Agevolazione
Next Post
Did Dr.

Leave a comment

Cancel reply

Recent Posts

  • Independent assessment to support establishment of a Future Entity
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
  • Istituzione delle causali contributo per il versamento, tramite modello F24, dei contributi all’INPS da destinare ad Enti Bilaterali (risoluzione n. 5)
  • Deadline for challenging your business rates valuation
  • Targeted financial support for aspiring social workers

Recent Comments

  1. validtheme on Digital Camera

Archives

  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Finance
  • internal news
  • Italy
  • Uncategorized
  • United Kingdom

Recent Posts

  • Independent assessment to support establishment of a Future Entity
    09 March, 2026Independent assessment to support
  • Predisposizione, da parte dell’Agenzia delle entrate, delle bozze dei registri IVA, delle liquidazioni periodiche dell’IVA e della dichiarazione annuale dell’IVA di cui all’articolo 4 del decreto legislativo 5 agosto 2015, n. 127. Ulteriore estensione del periodo sperimentale stabilito con il provvedimento del Direttore dell’Agenzia delle entrate n. 183994 dell’8 luglio 2021 (provvedimento)
    09 March, 2026Predisposizione, da parte dell’Agenzia
  • 09 March, 2026Istituzione delle causali contributo
  • Deadline for challenging your business rates valuation
    09 March, 2026Deadline for challenging your

Tags

Blue%20Finessence

Excellence decisively nay man yet impression for contrasted remarkably. There spoke happy for you are out. Fertile how old address did showing.

Contact Info

  • Address:CEO Blue FinEssence Ltd Piccadilly Circus 126 London
  • Email:director@bluefinessence.com
  • Phone:004407784915057

Copyright 2024 Bluefinessence. All Rights Reserved by Bluefinessence

  • About Us
  • Our Services